<DOC>
	<DOCNO>NCT00441298</DOCNO>
	<brief_summary>This phase IIb , two-arm , double-blinded , randomise , placebo control trial compare 1 % Tenofovir gel placebo gel expand safety effectiveness trial involve 900 young woman risk sexually transmit HIV infection . Participants provide supply single-use , pre-filled applicator accord randomisation . While study , participant ask apply first dose assign study gel within 12 hour prior coitus insert second dose soon possible within 12 hour coitus . All participant receive HIV risk reduction counselling , condom , syndromic treatment sexually transmitted infection , require .</brief_summary>
	<brief_title>Safety Effectiveness Study Candidate Vaginal Microbicide Prevention HIV</brief_title>
	<detailed_description>Purpose : To assess safety effectiveness tenofovir gel , candidate vaginal microbicide , sexually active woman risk human immunodeficiency virus ( HIV ) infection South Africa . Design : Phase IIb , two-arm , double-blind , randomise , control trial compare 1 % tenofovir gel placebo gel . Study Population : Sexually active , HIV-uninfected woman age 18 40 year South Africa Study Size : 900 woman Treatment Regimen : Participants provide supply single-use , pre-filled applicator accord randomisation . While study , participant ask apply first dose assign study product , 1 % tenofovir gel placebo gel , within 12 hour prior coitus insert second dose soon possible within 12 hour coitus . They advise use two dos gel 24-hour period . Study Duration : Approximately 30 month total . Accrual require approximately 14 month follow-up continue 92 incident HIV infection observe study , expect occur approximately 16 month end accrual period . Primary Objective : To evaluate effectiveness safety candidate vaginal microbicide , tenofovir gel , apply intravaginally woman , prevent sexually transmit HIV infection . Secondary Objectives : - To assess impact , , tenofovir gel incidence rate deep epithelial disruption - To assess impact , , tenofovir gel viral load woman become infected HIV trial . - To assess tenofovir resistance HIV seroconvertors trial - To ascertain impact , , tenofovir gel pregnancy rate outcomes - To assess impact , , product hold study exit HIV infection tenofovir resistance Ancillary Objective â€¢To assess impact , , tenofovir gel prevent sexually transmit infection , include herpes simplex virus type 2 ( HSV-2 ) human papillomavirus ( HPV ) infection . Study sit : - CAPRISA Vulindlela Clinical Research Site , KwaZulu-Natal , South Africa - CAPRISA eThekwini Clinical Research Site , Durban , South Africa</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 1840 year ( inclusive ) Able willing provide write informed consent screen , enrol , study . Able willing provide adequate locator information study retention purpose . Sexually active , define vaginal intercourse least twice past 30 day prior screen . HIV negative testing perform study staff within 30 day enrolment . Have negative pregnancy test perform study staff within 21 day enrolment Agree use nonbarrier form contraceptive Agree adhere study visit procedure History adverse reaction latex . Plans follow next 16 30 month ( depend anticipate date study completion ) : To travel away study site 30 consecutive day . To relocate away study site . To become pregnant To enrol study investigational product behaviour modification relate HIV prevention . Has creatinine clearance &lt; 50ml/min , estimate use method Cockcroft Gault ( 33 ) . Has active Hepatitis B infection ( since January 2009 ) Has clinically apparent pelvic examination finding ( observe study staff ) involve deep epithelial disruption . Otherwise eligible participant pelvic examination finding involve deep epithelial disruption may proceed enrolment finding resolve inclusion/exclusion met . Has past year participate research relate vaginally apply product/s . Has current STI symptom and/or reproductive tract infection require treatment , assess study staff . Otherwise eligible participant diagnose screen infection ( ) require treatment may enrol provide treatment commenced . Has condition , base opinion Investigator designee , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>microbicides</keyword>
	<keyword>safety</keyword>
	<keyword>effectiveness</keyword>
	<keyword>Tenofovir gel</keyword>
	<keyword>HIV</keyword>
	<keyword>young woman</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>